Study of Epstein-Barr virus-related pink eye
Part of Eyes & vision, Infections clinical trials.
This trial is studying a specific type of eye infection (pink eye) caused by the Epstein-Barr virus. It aims to better understand the condition and may help guide treatment for people with these symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years old or older.
- You have red, irritated eyes with bumps on the inside of your eyelids that started less than 4 weeks ago.
- A swab from your eye has tested positive for Epstein-Barr virus (EBV).
- Your doctor does not think another condition, like eye drops, is causing your symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks health outcomes over time in people who have a high level of the EBV virus in their blood. It may help researchers understand what happens in chronic (long-lasting) EBV infection and which outcomes to watch for.
This trial studies whether two products (2LEBV® and 2LXFS®) can improve ongoing fatigue in people who have evidence of an Epstein-Barr virus (EBV) infection. It aims to see if treatment helps reduce multiple related symptoms over follow-up.
This study looks at how the immune system’s antibodies behave after a first-time EBV infection, including whether they mistakenly react with the body’s own tissues. You might be offered a chance to help doctors understand why some people get longer or more intense symptoms from infectious mononucleosis.
This study collects medical information and blood samples from people with Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases to better understand how these conditions progress and respond to treatment. It includes a retrospective part (looking back at medical records) and a prospective part (following people forward in time).
This trial tests a new eye medication called SUM-191 for treating bacterial conjunctivitis (a bacterial infection that causes pink eye). The study has three parts: first testing safety in healthy people, then in people with the infection itself.
This trial tests an experimental mRNA vaccine (mRNA-1189) to see if it can prevent Epstein-Barr virus (EBV) infection. It is for healthy adults 18 to 30 years old.
Hear when a new Conjunctivitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.